
Joel Picus MD
Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology
Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine
Join to View Full Profile
4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192
Dr. Picus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1987 - 1990
- Duke University HospitalResidency, Internal Medicine, 1984 - 1987
- Harvard Medical SchoolClass of 1984
Certifications & Licensure
- MO State Medical License 1991 - 2026
- NC State Medical License 1986 - 2025
- CA State Medical License 1987 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Clinical Trials
- Hormone Therapy in Treating Patients With Prostate Cancer Start of enrollment: 1998 May 01
- Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2001 Jun 01
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.Timothy Gilligan, Daniel W Lin, Nabil Adra, Aditya Bagrodia, Darren R Feldman
Journal of the National Comprehensive Cancer Network. 2025-04-01 - A phase I dose escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear cell renal cell carcinoma.Sumanta K Pal, Alice Bernard-Tessier, Peter Grell, Xin Gao, Ritesh R Kotecha
Clinical Cancer Research. 2025-03-05 - 7 citationsAbiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang
Clinical Cancer Research. 2024-10-01
Press Mentions
- Defactinib Combined with Pembrolizumab and Gemcitabine in Patients with Advanced CancerApril 18th, 2016
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: